Trevi Therapeutics (TRVI) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order with introductions of board members, executive officers, legal counsel, auditor, and inspector of elections.

• Rules of conduct and forward-looking statement disclaimers were highlighted at the outset.

Shareholder proposals

• Five proposals were presented: election of a Class I director, ratification of the auditor, advisory approval of executive compensation, approval of an amended stock incentive plan, and an amendment to increase authorized shares.

Overview of voting outcomes

• Quorum established with 88.92% of shares represented.

• All proposals passed: director elected, auditor ratified, executive compensation approved, stock incentive plan approved, and authorized shares increased from 200 million to 400 million.

• Final vote results to be filed in a Form 8-K within four business days.